Resigratinib (KIN-3248) is an experimental anticancer medication which acts as a fibroblast growth factor receptor inhibitor (FGFRi) and is in early stage human clinical trials.[1][2][3]
Identifiers | |
---|---|
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C26H27F2N7O3 |
Molar mass | 523.545 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Franovic A, Mohan A, Uryu S, Wu Q, Jiang P, Miller N, et al. (February 2022). "Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations". Journal of Clinical Oncology. 40 (4_suppl): 461. doi:10.1200/JCO.2022.40.4_suppl.461.
- ^ Harding JJ, Perez CA, Kato S, Sharma M, Garmezy B, Quah CS, et al. (February 2023). "First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations". Journal of Clinical Oncology. 41 (4_suppl): TPS637-TPS637. doi:10.1200/JCO.2023.41.4_suppl.TPS637. S2CID 256257314.
- ^ Wang Z, Anderson KS (2022). "Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer". Cancer Journal (Sudbury, Mass.). 28 (5): 354–362. doi:10.1097/PPO.0000000000000615. PMC 9523489. PMID 36165723.